These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 14719194

  • 41. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
    Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO, Bathon J.
    Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
    [Abstract] [Full Text] [Related]

  • 42. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis.
    Stern R, Wolfe F.
    J Rheumatol; 2004 Aug; 31(8):1538-45. PubMed ID: 15290732
    [Abstract] [Full Text] [Related]

  • 43. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [Abstract] [Full Text] [Related]

  • 44. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis.
    Sany J, Kaiser MJ, Jorgensen C, Trape G.
    Ann Rheum Dis; 2005 Nov; 64(11):1647-9. PubMed ID: 16227416
    [Abstract] [Full Text] [Related]

  • 45. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.
    Hoffmann JH, Hartmann M, Enk AH, Hadaschik EN.
    Br J Dermatol; 2011 Dec; 165(6):1355-8. PubMed ID: 21801160
    [Abstract] [Full Text] [Related]

  • 46. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
    Flendrie M, Creemers MC, van Riel PL.
    Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
    [Abstract] [Full Text] [Related]

  • 47. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY, Browning JC, Larsen F, Hsu S.
    Dermatol Online J; 2008 Sep 15; 14(9):12. PubMed ID: 19061594
    [Abstract] [Full Text] [Related]

  • 48. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis.
    van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink G, Dijkmans BA, Aarden LA.
    Ann Rheum Dis; 2007 Feb 15; 66(2):253-6. PubMed ID: 16793840
    [Abstract] [Full Text] [Related]

  • 49. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.
    Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N.
    Arthritis Res Ther; 2004 Feb 15; 6(6):R535-43. PubMed ID: 15535831
    [Abstract] [Full Text] [Related]

  • 50. Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease.
    Elezoglou A, Kafasi N, Kaklamanis PH, Theodossiadis PG, Kapsimali V, Choremi E, Vaiopoulos G, Sfikakis PP.
    Clin Exp Rheumatol; 2007 Feb 15; 25(4 Suppl 45):S65-9. PubMed ID: 17949554
    [Abstract] [Full Text] [Related]

  • 51. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab.
    Kosmač M, Avčin T, Toplak N, Simonini G, Cimaz R, Curin Šerbec V.
    Pediatr Res; 2011 Mar 15; 69(3):243-8. PubMed ID: 21131896
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate.
    Sellam J, Allanore Y, Batteux F, Deslandre CJ, Weill B, Kahan A.
    Joint Bone Spine; 2005 Jan 15; 72(1):48-52. PubMed ID: 15681248
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease.
    Nancey S, Blanvillain E, Parmentier B, Flourié B, Bayet C, Bienvenu J, Fabien N.
    Inflamm Bowel Dis; 2005 Nov 15; 11(11):986-91. PubMed ID: 16239844
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction.
    Vultaggio A, Matucci A, Nencini F, Pratesi S, Maggi E.
    Intern Emerg Med; 2012 Sep 15; 7 Suppl 2():S77-9. PubMed ID: 21544533
    [No Abstract] [Full Text] [Related]

  • 59. Immunogenicity and Lupus-Like Autoantibody Production Can Be Linked to Each Other along With Type I Interferon Production in Patients with Rheumatoid Arthritis Treated With Infliximab: A Retrospective Study of a Single Center Cohort.
    Ishikawa Y, Fujii T, Ishikawa SK, Yukawa N, Hashimoto M, Furu M, Ito H, Ohmura K, Mimori T.
    PLoS One; 2016 Sep 15; 11(9):e0162896. PubMed ID: 27643491
    [Abstract] [Full Text] [Related]

  • 60. New-onset vitiligo during long-term, stable infliximab treatment of pityriasis rubra pilaris.
    Mattox AR, Chappell JA, Hurley MY.
    J Drugs Dermatol; 2013 Feb 15; 12(2):217-9. PubMed ID: 23377397
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.